226 related articles for article (PubMed ID: 31395086)
1. HDACs control RUNX2 expression in cancer cells through redundant and cell context-dependent mechanisms.
Manzotti G; Torricelli F; Donati B; Sancisi V; Gugnoni M; Ciarrocchi A
J Exp Clin Cancer Res; 2019 Aug; 38(1):346. PubMed ID: 31395086
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase Inhibitors Repress Tumoral Expression of the Proinvasive Factor RUNX2.
Sancisi V; Gandolfi G; Ambrosetti DC; Ciarrocchi A
Cancer Res; 2015 May; 75(9):1868-82. PubMed ID: 25769725
[TBL] [Abstract][Full Text] [Related]
3. Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage.
Ozaki T; Wu D; Sugimoto H; Nagase H; Nakagawara A
Cell Death Dis; 2013 Apr; 4(4):e610. PubMed ID: 23618908
[TBL] [Abstract][Full Text] [Related]
4. RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN.
Sancisi V; Manzotti G; Gugnoni M; Rossi T; Gandolfi G; Gobbi G; Torricelli F; Catellani F; Faria do Valle I; Remondini D; Castellani G; Ragazzi M; Piana S; Ciarrocchi A
Nucleic Acids Res; 2017 Nov; 45(19):11249-11267. PubMed ID: 28981843
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner.
Jensen ED; Schroeder TM; Bailey J; Gopalakrishnan R; Westendorf JJ
J Bone Miner Res; 2008 Mar; 23(3):361-72. PubMed ID: 17997710
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase co-repressor complex control of Runx2 and bone formation.
Jensen ED; Nair AK; Westendorf JJ
Crit Rev Eukaryot Gene Expr; 2007; 17(3):187-96. PubMed ID: 17725488
[TBL] [Abstract][Full Text] [Related]
7. Thyroid Hormone Receptor-β (TRβ) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer.
Carr FE; Tai PW; Barnum MS; Gillis NE; Evans KG; Taber TH; White JH; Tomczak JA; Jaworski DM; Zaidi SK; Lian JB; Stein JL; Stein GS
Endocrinology; 2016 Aug; 157(8):3278-92. PubMed ID: 27253998
[TBL] [Abstract][Full Text] [Related]
8. Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.
Schäfer C; Göder A; Beyer M; Kiweler N; Mahendrarajah N; Rauch A; Nikolova T; Stojanovic N; Wieczorek M; Reich TR; Tomicic MT; Linnebacher M; Sonnemann J; Dietrich S; Sellmer A; Mahboobi S; Heinzel T; Schneider G; Krämer OH
Cell Signal; 2017 Jan; 29():218-225. PubMed ID: 27838375
[TBL] [Abstract][Full Text] [Related]
9. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
10. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
11. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter.
Westendorf JJ; Zaidi SK; Cascino JE; Kahler R; van Wijnen AJ; Lian JB; Yoshida M; Stein GS; Li X
Mol Cell Biol; 2002 Nov; 22(22):7982-92. PubMed ID: 12391164
[TBL] [Abstract][Full Text] [Related]
12. Transcription factor Runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas.
Niu DF; Kondo T; Nakazawa T; Oishi N; Kawasaki T; Mochizuki K; Yamane T; Katoh R
Lab Invest; 2012 Aug; 92(8):1181-90. PubMed ID: 22641097
[TBL] [Abstract][Full Text] [Related]
13. HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma.
Ramakrishnan S; Ku S; Ciamporcero E; Miles KM; Attwood K; Chintala S; Shen L; Ellis L; Sotomayor P; Swetzig W; Huang R; Conroy D; Orillion A; Das G; Pili R
BMC Cancer; 2016 Aug; 16():617. PubMed ID: 27506904
[TBL] [Abstract][Full Text] [Related]
14. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
15. Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer.
Feng W; Lu Z; Luo RZ; Zhang X; Seto E; Liao WS; Yu Y
Int J Cancer; 2007 Apr; 120(8):1664-8. PubMed ID: 17230502
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism.
Hrgovic I; Doll M; Pinter A; Kaufmann R; Kippenberger S; Meissner M
Exp Dermatol; 2017 Feb; 26(2):194-201. PubMed ID: 27487811
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Runx2 by Histone Deacetylases in Bone.
Vishal M; Ajeetha R; Keerthana R; Selvamurugan N
Curr Protein Pept Sci; 2016; 17(4):343-51. PubMed ID: 27072566
[TBL] [Abstract][Full Text] [Related]
18. HDAC6 inactivates Runx2 promoter to block osteogenesis of bone marrow stromal cells in age-related bone loss of mice.
Ma C; Gao J; Liang J; Dai W; Wang Z; Xia M; Chen T; Huang S; Na J; Xu L; Feng S; Dai K; Liu G
Stem Cell Res Ther; 2021 Aug; 12(1):484. PubMed ID: 34454588
[TBL] [Abstract][Full Text] [Related]
19. A RUNX2-HDAC1 co-repressor complex regulates rRNA gene expression by modulating UBF acetylation.
Ali SA; Dobson JR; Lian JB; Stein JL; van Wijnen AJ; Zaidi SK; Stein GS
J Cell Sci; 2012 Jun; 125(Pt 11):2732-9. PubMed ID: 22393235
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase 8 suppresses osteogenic differentiation of bone marrow stromal cells by inhibiting histone H3K9 acetylation and RUNX2 activity.
Fu Y; Zhang P; Ge J; Cheng J; Dong W; Yuan H; Du Y; Yang M; Sun R; Jiang H
Int J Biochem Cell Biol; 2014 Sep; 54():68-77. PubMed ID: 25019367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
